Burn rate is the speed at which a company consumes its cash reserves. Gross burn = total monthly operating expenses; net burn = gross burn minus revenue. Burn usually rises sharply during pivotal trials and commercial launch. Investors compare burn to milestone progress to judge capital efficiency. Tracking burn by program helps leaders decide which projects to pause if funding is tight.

Why it matters

Pre-revenue MedTech companies have only gross burn. As commercial sales begin, net burn becomes the meaningful metric.

Common pitfalls

•Confusing burn rate with profitability; a company can have a high burn rate while still being profitable if revenue significantly outpaces expenses.
•Underestimating the financial resources required for clinical trials, regulatory submissions, and post-market surveillance activities.
•Failing to account for unexpected delays in regulatory approvals or market adoption, which can significantly extend the period of cash consumption.
•Overlooking the impact of supply chain disruptions or quality issues on cash flow, as these can necessitate unplanned expenditures.

Sources

Silicon Valley Bank - Healthcare Reports · SVB
PitchBook - MedTech Coverage · PitchBook
NVCA Model Documents · NVCA
SEC capital-raising glossary: burn rate · U.S. Securities and Exchange Commission

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.